Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: Results of the open-label, controlled, randomized phase II CORE study

Neuro-Oncology

Volumn 17, Issue 5, 2015, Pages 708-717

  Nabors, L Burt ^a   Fink, Karen L ^b   Mikkelsen, Tom ^c   Grujicic, Danica ^d   Tarnawski, Rafal ^e   Nam, Do Hyun ^f   Mazurkiewicz, Maria ^g   Salacz, Michael ^h,p   Ashby, Lynn ⁱ   Zagonel, Vittorina ^j   Depenni, Roberta ^k   Perry, James R ^l   Hicking, Christine ^m   Picard, Martin ^m   Hegi, Monika E ⁿ   Lhermitte, Benoit ⁿ   Reardon, David A ^o  

^a The University of Alabama at Birmingham   (United States)

^b BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^c HENRY FORD HOSPITAL   (United States)

^d UNIVERSITY OF BELGRADE   (Serbia)

^e INSTITUTE OF ONCOLOGY   (Poland)

^f Samsung Medical Center   (South Korea)

^g Centrum Onkologii Ziemi Lubelskiej   (Poland)

^h ST LUKE S HOSPITAL   (United States)

ⁱ BARROW NEUROLOGICAL INSTITUTE   (United States)

^j VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^k UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^l SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^m MERCK KGAA   (Germany)

ⁿ LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^o DANA FARBER CANCER INSTITUTE   (United States)

^p UNIVERSITY OF KANSAS   (United States)

more..

Author keywords

cilengitide; newly diagnosed glioblastoma; randomized phase II study; unmethylated MGMT promoter

Indexed keywords

CILENGITIDE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; TEMOZOLOMIDE; ANTINEOPLASTIC AGENT; DACARBAZINE; DNA LIGASE; DNA METHYLTRANSFERASE; MGMT PROTEIN, HUMAN; SNAKE VENOM; TUMOR SUPPRESSOR PROTEIN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; CHEMORADIOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GLIOBLASTOMA; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; OVERALL SURVIVAL; PANCYTOPENIA; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; PROMOTER REGION; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; THROMBOCYTOPENIA; TREATMENT OUTCOME; ANALOGS AND DERIVATIVES; BRAIN NEOPLASMS; CLINICAL TRIAL; DNA METHYLATION; GENETICS; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; DACARBAZINE; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; FEMALE; GLIOBLASTOMA; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PROMOTER REGIONS, GENETIC; SNAKE VENOMS; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEINS;

EID: 84928882474     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nou356     Document Type: Article

References (19)

1. Ostrom QT, Gittleman H, Farahet P, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2006-2010. Neuro Oncol. 2013;15(suppl 2):ii1-ii56.
2. Haar CP, Hebbar P, Wallace GC 4th, et al. Drug resistance in glioblastoma: a mini review. Neurochem Res. 2012;37(6):1192-1200.
3. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987-996.
4. National Comprehensive Cancer Network. 2014 NCCN clinical practice guidelines in oncology (NCCN Guidelines): central nervous system cancers. Version 2.2014, Comprehensive Cancer Network, Fort Washington, PA. Available at http://www.nccn.org/. Accessed March 5, 2015.
5. Hegi ME, Diserens AC, Godard S, et al. Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res. 2004;10(6):1871-1874.
6. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005; 352(10):997-1003.
7. Nagane M, Kobayashi K, Ohnishi A, et al. Prognostic significance of O6-methylguanine-DNA methyltransferase protein expression in patients with recurrent glioblastoma treated with temozolomide. Jpn J Clin Oncol. 2007;37(12):897-906.
8. Smith JW. Cilengitide Merck. Curr Opin Investig Drugs. 2003;4(6): 741-745.
9. Desgrosellier JS, Cheresh DA. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer. 2010;10(1):9-22.
10. Bello L, Francolini M, Marthyn P, et al. Alpha(v)beta3 and alpha(v)beta5 integrin expression in glioma periphery. Neurosurgery. 2001;49(2):380-389.
11. Nabors LB, Mikkelsen T, Rosenfeld SS, et al. Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma. J Clin Oncol. 2007;25(13):1651-1657.
12. Reardon DA, Fink KL, Mikkelsen T, et al. Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J Clin Oncol. 2008; 26(34):5610-5617.
13. Stupp R, Hegi ME, Neyns B, et al. Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. J Clin Oncol. 2010;28(16): 2712-2718.
14. Nabors LB, Mikkelsen T, Hegi ME, et al. A safety run-in and randomized phase 2 study of cilengitide combined with chemoradiation for newly diagnosed glioblastoma (NABTT 0306). Cancer. 2012;118(22):5601-5607.
15. Gilbert MR, Kuhn J, Lamborn KR, et al. Cilengitide in patients with recurrent glioblastoma: the results of NABTC 03-02, a phase II trial with measures of treatment delivery. J Neurooncol. 2012; 106(1):147-153.
16. Stupp R, Hegi ME, Gorlia T, et al. Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15(10):1100-1108.
17. Mikkelsen T, Brodie C, Finniss S, et al. Radiation sensitization of glioblastoma by cilengitide has unanticipated scheduledependency. Int J Cancer. 2009;124(11):2719-2727.
18. Macdonald DR, Cascino TL, Schold SC Jr, et al. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990;8(7):1277-1280.
19. Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010;28(11): 1963-1972.